LMAT vs ZBH
LeMaitre Vascular, Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
LMAT
LeMaitre Vascular, Inc.
57
Watch
VS
| Metric | LMAT | ZBH |
|---|
| AI Score |
57
|
69
|
| Price |
$82.83
|
$97.22
|
| P/E Ratio |
28.57×
|
23.54×
|
| ROE |
14.7%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.9%
|
69.9%
|
| Debt / Equity |
0.45×
|
0.59×
|
| Dividend Yield |
1.1%
|
1.0%
|
| RSI (14) |
31.2
|
63.1
|
| Beta |
0.524
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for LMAT versus ZBH.
ZBH leads by 12 points.
ZBH scores 69/100 (Buy) versus LMAT at 57/100 (Watch).
LMAT Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 38.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 16.4% shows genuine earnings power backing the valuation — Value
- EPS growing 34.4% YoY — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 28.6 is moderate-to-rich — Value
- Price-to-book of 4.7x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical